Медицинская литература. Новинки

 

 

 

 

 

 

Современный взгляд на проблему диагностики и лечения медуллярного рака щитовидной железы

Вы можете загрузить полный текст статьи в формате pdf

За последние 4 года ведущие эндокринологические сообщества разных стран выпустили рекомендации, посвященные диагностике и лечению медуллярного рака щитовидной железы. Статья охватывает большинство аспектов ведения пациентов с данной патологией

Ключевые слова:
медуллярный рак щитовидной железы, синдром множественных эндокринных неоплазий 2 типа, кальцитонин, раковоэмбриональный антиген, RET-протоонкоген.

Литература:
1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National
Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83:2638
2648.
2. Leboulleux S, Baudin B, Travagli JP, Schlumberger M.
Medullary thyroid carcinoma. Clin Endocrinol (Oxf).
2004;61:299310.
3. Kebebew E, Ituarte PH, Siperstein AE et al. Medullary thyroid
carcinoma: clinical characteristics, treatment, prognostic
factors, and a comparison of staging systems. Cancer.
2000;88:11391148.
4. Xu L, Wang WB, Zhao YP et al. Medullary thyroid carcinoma
with nodular goiter carries an excellent prognosis. J Surg
Oncol. 2012;106:169173.
5. PylayevaGupta Y, Grabocka E, BarSagi D. RAS oncogenes:
weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761
774.
6. Pelizzo MR, Boschin IM, Bernante P et al. Natural history,
diagnosis, treatment and outcome of medullary thyroid can
cer: 37 years experience on 157 patients. Eur J Surg Oncol.
2007;33:493497.
7. Baloch ZW, LiVolsi VA. Prognostic factors in welldifferentia
ted follicularderived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11:637645.
8. Paszko Z, Sromek M, Czetwertynska M et al. The occurrence
and the type of germline mutations in the RET gene in
patients with medullary thyroid carcinoma and their un
affected kindreds from Central Poland. Cancer Invest.
2007;25:742749.
9. Bergant D, Hocevar M, Besic N et al. Hereditary medullary
thyroid cancer in Slovenia – genotypephenotype correlations. Wien Klin Wochenschr. 2006;118:411416.
10. Ильин АА, Румянцев ПО, Исаев ПА и др. Спорадический
и семейный варианты медуллярного рака щитовидной
железы. Проблемы эндокринологии. 2003;49(5):4547.
11. Ильин АА, Румянцева УВ, Васильев ЕВ и др. Результаты
генетического скрининга наследственных форм медуллярного рака щитовидной железы. 15й Российский симпозиум по хирургической эндокринологии, г. Рязань.
2005;153154.
12. Бржезовский ВЖ. Современная стратегия диагностики и
лечения медуллярного рака щитовидной железы: дис. …
докт. мед. наук. ГУ Российский онкологический научный
центр РАМН. М., 2004; 42152.
13. Mulligan LM, Kwok JB, Healey CS et al. Germline mutations
of the RET protooncogene in multiple endocrine neoplasia
type 2A. Nature. 1993;363:458460.
14. DonisKeller H, Dou S, Chi D et al. Mutations in the RET
protooncogene are associated with MEN 2A and FMTC. Hum
Mol Genet. 1993;2:851856.
15. Romei C, Pardi E, Cetani F, Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol.
2012:115.
16. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis
and therapy of MEN type 1 and type 2. J Clin Endocrinol
Metab. 2001;86:56585671.
17. Modigliani E, Cohen R, Campos JM et al. Prognostic factors
for survival and for biochemical cure in medullary thyroid car
cinoma: results in 899 patients. The GETC Study Group.
Groupe d’^etude des tumeurs a` calcitonine. Clin Endocrinol.
1998;48:265273.
18. Iihara M, Yamashita T, Okamoto T et al. A nationwide clinical
survey of patients with multiple endocrine neoplasia type 2
and familial medullary thyroid carcinoma in Japan. Jpn J Clin
Oncol. 1997;27:128134.
19. Юкина МЮ, Гончаров НП, Бельцевич ДГ, Трошина ЕА.
Множественная эндокринная неоплазия 2го типа. Про
блемы эндокринологии. 2011;6:2126.
20. Farndon JR, Leight GS, Dilley WG et al. Familial medullary
thyroid carcinoma without associated endocrinopathies: a
distinct clinical entity. Br J Surg. 1986;73:278281.
21. Eng C, Clayton D, Schuffenecker I et al. The relationship
between specific RET protooncogene mutations and di
sease phenotype in multiple endocrine neoplasia type 2.
International RET mutation consortium analysis. JAMA.
1996;276:15751579.
22. Carlson KM, Bracamontes J, Jackson CE et al. Parentoforigin effects in multiple endocrine neoplasia type 2B. Am J
Hum Genet. 1994;55:10761082.
23. Kaufman FR, Roe TF, Isaacs H, Weitzman JJ. Metastatic
medullary thyroid carcinoma in young children with mucosal
neuroma syndrome. Pediatrics. 1982;70:263267.
24. Machens A, Brauckhoff M, Holzhausen HJ et al. Codonspecific development of pheochromocytoma in multiple
endocrine neoplasia type 2. J Clin Endocrinol Metab.
2005;90:39994003.
25. Ciampi R, Mian C, Fugazzola L et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer
series. Thyroid. 2013;23(1):5057.
26. Agrawal N, Jiao Y, Sausen M et al. Exomic sequencing of
medullary thyroid cancer reveals dominant and mutually
exclusive oncogenic mutations in RET and RAS. J Clin
Endocrinol Metab. 2013;98(2):364369.
27. Kloos RT, Eng Ch, Evans DB et al. Medullary Thyroid Cancer:
Management Guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565512.
28. Cohen MS, Moley JF. Surgical treatment of medullary thyroid
carcinoma. J Internal Med. 2003;253(6):616626.
29. Cai S, Liu H, Li W et al. Ultrasonographic features of medullary
thyroid carcinoma and their diagnostic values. Chin Med J.
2010;123(21):30743078.
30. Ильин АА, Втюрин БМ, Румянцев ПО. Ультразвуковая картина дифференцированного рака щитовидной железы у
детей и подростков в загрязненных радионуклидами районах России. Ультразвуковая диагностика. 1997;4:6874.
31. Kim SH, Kim BS, Jung SL et al. Ultrasonographic findings of
medullary thyroid carcinoma: a comparison with papillary thy
roid carcinoma. Korean J Radiol. 2009;10:101105.
32. Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma:
comparison with papillary thyroid carcinoma and application
of current sonographic criteria. Am J Roentgenol.
2010;194:10901094.
33. Кондратьева ТТ. Возможности цитологического метода в
диагностике нетипичных вариантов рака щитовидной железы. Рак щитовидной железы. Eso Red Square Seminar.
Москва, 2004; 2931.
34. Chang TC, Wu SL, Hsiao YL. Medullary thyroid carcinoma:
pitfalls in diagnosis by fine needle aspiration cytology and
relationship of cytomorphology to RET protooncogene mutations. Acta Cytolog. 2005;49:477482.
35. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of
medullary carcinoma of the thyroid gland. Diagn Cytopathol.
2000;22:351358.
36. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis
of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg
Oncol. 2005;91:5660.
37. Niccoli P, WionBarbot N, Caron P et al. Interest of routine
measurement of serum calcitonin: study in a large series of
thyroidectomized patients. The French Medullary Study
Group. J Clin Endocrinol Metab. 1997;82:338341.
38. Elisei R, Bottici V, Luchetti F et al. Impact of routine measure
ment of serum calcitonin on the diagnosis and outcome of
medullary thyroid cancer: experience in 10,864 patients with
nodular thyroid disorders. J Clin Endocrinol Metab. 2004;
89:163168.
39. Boi F, Maurelli I, Pinna G et al. Calcitonin measurement in
washout fluid from fine needle aspiration of neck masses in
patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(6):21152118.
40. Исаев ПА. Медуллярный рак щитовидной железы (комплексная лучевая диагностика и лечение): дисс. … канд.
мед. наук. ГУ Медицинский радиологический научный
центр. Обнинск, 2004;915.
41. Massaro F, Dolcino M, Degrandi R et al. Calcitonin assay in
washout fluid after fineneedle aspiration biopsy in patients
with a thyroid nodule and borderline value of the hormone.
J Endocrinol Invest. 2009;32(4):308312.
42. Chambon G, Alovisetti C, IdouxLouche C et al. The use of
preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid
disorders: results from 2733 consecutive patients. J Clin
Endocrinol Metab. 2011;96(1):7581.
43. Valle LA, Kloos RT. The prevalence of occult medullary thyroid
carcinoma at autopsy. J Clin Endocrinol Metab. 2011;96(1):
109113.
44. Ahmed SR, Ball DW. Incidentally discovered medullary thy
roid cancer: diagnostic strategies and treatment. J Clin
Endocrinol Metab. 2011;96:12371245.
45. Beressi N, Campos JM, Beressi JP. Sporadic medullary
microcarcinoma of the thyroid: a retrospective analysis of
eighty cases. Thyroid. 1998;8:10391044.
46. Kaserer K, Scheuba C, Neuhold N. Sporadic versus familial
medullary thyroid microcarcinoma: a histopathologic study of
50 consecutive patients. Am J Surg Pathol. 2001;25:
12451251.
47. Peix JL, Braun P, Saadat M. et al. Occult micro medullary thy
roid carcinoma: therapeutic strategy and followup. Wld J
Surg. 2000;24:13731376.
48. Hamy A, Pessaux P, Miralli@e E. Central neck dissection in the
management of sporadic medullary thyroid microcarcinoma.
Eur J Surg Oncol. 2005;31:774777.
49. Henry JF, Denizot A, Puccini M. Latent subclinical medullary
thyroid carcinoma: diagnosis and treatment. World J Surg.
1998;22:752757.
50. Pillarisetty VG, Katz SC, Ghossein RA et al. Micromedullary
thyroid cancer: how micro is truly micro? Ann Surg Oncol.
2009;16:28752881.
51. Costante G, Meringolo D, Durante C et al. Predictive value of
serum calcitonin levels for preoperative diagnosis of
medullary thyroid carcinoma in a cohort of 5817 consecutive
patients with thyroid nodules. J Clin Endocrinol Metab. 2007;
92:450455.
52. Pacini F, Fontanelli M, Fugazzola L et al. Routine measurement
of serum calcitonin in nodular thyroid diseases allows the pre
operative diagnosis of unsuspected sporadic medullary thyroid
carcinoma. J. Clin. Endocrinol. Metab. 1994;78: 826829.
53. Rieu M, Lame MC, Richard A et al. Prevalence of sporadic
medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of
thyroid nodules. Clin Endocrinol (Oxf). 1995;42:453460.
54. Vierhapper H, Raber W, Bieglmayer C et al. Routine measurement of plasma calcitonin in nodular thyroid diseases.
J Clin Endocrinol Metab. 1997;82:15891593.
55. Kaserer K, Scheuba C, Neuhold N et al. Ccell hyperplasia
and medullary thyroid carcinoma in patients routinely
screened for serum calcitonin. Am J Surg Pathol. 1998;22:
722728.
56. Ozgen AG, Hamulu F, Bayraktar F et al. Evaluation of routine
basal serum calcitonin measurement for early diagnosis of
medullary thyroid carcinoma in seven hundred seventy three
patients with nodular goiter. Thyroid. 1999;9:579582.
57. Привалов ВА, Кулеев ИА, Сергийко СВ и др. Клиникоанатомические особенности рака щитовидной железы.
35летний опыт хирургического лечения. Современные
аспекты хирургической эндокринологии. Рязань, 2005;
274280.
58. Hahm JR, Lee MS, Min YK et al. Routine measurement of
serum calcitonin is useful for early detection of medullary thy
roid carcinoma in patients with nodular thyroid diseases.
Thyroid. 2001;11:7380.
59. D’Herbomez M, Caron P, Bauters C. French Group GTE
(Groupe des Tumeurs Endocrines). Reference range of serum
calcitonin levels in humans: influence of calcitonin assays,
sex, age, and cigarette smoking. Eur J Endocrinol.
2007;157:749755.
60. Kotzmann H, Schmidt A, Scheuba C. Basal calcitonin levels
and the response to pentagastrin stimulation in patients after
kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid. 1999;9:943947.
61. Erdogan MF, Gullu S, Baskal N et al. Omeprazole: calcitonin
stimulation test for the diagnosis followup and family screen
ing in medullary thyroid carcinoma. J Clin Endocrinol Metab.
1997;82:897899.
62. LiVolsi VA. Ccell hyperplasia = neoplasia. J Clin Endocrinol
Metab. 1997;82:3941.
63. Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of
genderspecific calcitonin thresholds in screening for occult
sporadic medullary thyroid cancer. Endocr Relat Cancer.
2009;16:12911298.
64. Wells Jr SA, Baylin SB, Linehan WM et al. Provocative agents
and the diagnosis of medullary carcinoma of the thyroid
gland. Ann Surg. 1978;188:139141.
65. Gharib H, Kao PC. Determination of silicapurified plasma
calcitonin for the detection and management of medullary
thyroid carcinoma: comparison of two provocative tests.
Mayo Clin Proc. 1987;62:373378.
66. Doyle P, Duren C, Nerlich K et al. Potency and tolerance of
calcitonin stimulation with highdose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab. 2009;
94:29702974.
67. Colombo C, Verga U, Perrino M et al. Highdose calcium and
pentagastrin tests in patients with cured or persistent
medullary thyroid cancer and in controls: comparison of the
efficacy and the tolerance. Abstract 14th Annual International
Thyroid Congress. Paris, 2010;0923.
68. Cheung K, Roman SA, Wang TS et al. Calcitonin measure
ment in the evaluation of thyroid nodules in the United States:
a costeffectiveness and decision analysis. J Clin Endocrinol
Metab. 2008;93:21732180.
69. Iacobone M, NiccoliSire P, Sebag F et al. Can sporadic
medullary thyroid carcinoma be biochemically predicted?
Prospective analysis of 66 operated patients with elevated
serum calcitonin levels. Wld J Surg. 2002;26:886890.
70. Vierhapper H, Niederle B, Bieglmayer C et al. Early diagnosis
and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid
disorders. Thyroid. 2005;15:12671272.
71. Ванушко ВЭ, Бельцевич ДГ, Кузнецов НС и др. Кальцитонин – маркер адекватности хирургического лечения медуллярного рака щитовидной железы. Клиническая тире
оидология. 2003;1(2):2427.
72. Ванушко ВЭ, Кузнецов НС, Бельцевич ДГ и др. Прицельная тонкоигольная пункционная биопсия в диагностике
рака щитовидной железы. Хирургия. 2003;10:6772.
73. Cooper DS, Doherty GM, Haugen BR et al. Management
Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009;19(11):148.
74. Elisei R, Romei C. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC:
european comments to the guidelines of the American
Thyroid Association. Thyroid Research. 2013;6(Suppl 1):S2.
75. Румянцев ПО, Ильин АА, Румянцева УВ, Газизова ДО.
Факторы клинического прогноза медуллярного рака щитовидной железы. Опухоли головы и шеи. 2011;4:4854.
76. Исаев ПА, Медведев ВС, Ильин АА и др. Динамика уровня кальцитонина в периферической крови у больных
медуллярным раком щитовидной железы. Российский
онкологический журнал. 2002;6:3133.
77. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid.
2000;10:919922.
78. Pacini F, Basolo F, Elisei R et al. Medullary thyroid cancer. An
immunohistochemical and humoral study using six separate
antigens. Am J Clin Pathol. 1991;95:300308.
79. Elisei R, Lorusso L, Romei C et al. Medullary thyroid cancer
secreting carbohydrate antigen 199 (Ca 199): a fatal case
report. J Clin Endocrinol Metab. 2013;98(9):35503554.
80. Locker GY, Hamilton S, Harris J et al. Update of recommendations for the use of tumor markers in gastrointestinal can
cer. J Clin Oncol. 2006;24(9):53135327.
81. Larena A, Vierbuchen M, Fischer R. Blood group antigen
expression in malignant tumors of the thyroid: a parallel
between medullary and nonmedullary carcinomas. Langen
becks Arch Chir. 1995;380:269272.
82. Milman S, Whitney KD, Fleischer N. Metastatic medullary thy
roid cancer presenting with elevated levels of CA 199 and CA
125. Thyroid. 2011;21:913916.
83. Wiench M, Wygoda Z, Gubala E et al. Estimation of risk of
inherited medullary thyroid carcinoma in apparent sporadic
patients. J Clin Oncol. 2001;19:13741380.
84. Erdogan M, Gursoy A, Gullu S et al. Clinical and genetic experience in Turkish multiple endocrine neoplasia type 2 families.
Endocrinologist. 2007;17:273277.
85. Hyer SL, Vini L, A’Hern R, Harmer C. Medullary thyroid can
cer: multivariate analysis of prognostic factors influencing
survival. Eur J Surg Oncol. 2000;26:686690.
86. Дедов ИИ, Трошина ЕА, Мазурина НВ и др. Молекулярногенетические аспекты новообразований щитовидной железы. Проблемы эндокринологии. 2000;46(2):2230.
87. Васильев ЕВ, Румянцев ПО, Полякова ЕЮ и др. Молекулярная диагностика мутаций протоонкогена RET при различных формах медуллярного рака щитовидной железы.
Молекулярная медицина. 2004;4:5460.
88. Elisei R, Romei C, Cosci B et al. Brief report: RET genetic
screening in patients with medullary thyroid cancer and their
relatives: experience with 807 individuals at one center. J Clin
Endocrinol Metab. 2007;92(12):47254729.
89. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type
2 and RET: from neoplasia to neurogenesis. J Med Genetics.
2000;37(11):817827.
90. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7(1):3545.
91. Амосенко ФА, Калинин ВН, Козлова ВМ и др. Мутации
в протоонкогене RET у больных с медуллярным раком
щитовидной железы и возможности доклинической диагностики и профилактического лечения носителей этого
заболевания. Вестник РОНЦ имени Н.Н. Блохина РАМН.
2000;11(1):2026.
92. Heshmati HM, Gharib H, Khosla S et al. Genetic testing in
medullary thyroid carcinoma syndromes: mutation types and
clinical significance. Mayo Clin Proc. 1997;72:430436.
93. Marsh DJ, Mulligan LM, Eng C. RET protooncogene mutations in multiple endocrine neoplasia type 2 and medullary
thyroid carcinoma. Horm Res. 1997;47:168178.
94. Romei C, Mariotti S, Fugazzola L et al. ItaMEN network,
Multiple endocrine neoplasia type 2 syndromes (MEN 2):
results from the ItaMEN network analysis on the prevalence of
different genotypes and phenotypes. Eur J Endocrinol.
2010;163(2):301308.
95. Mulligan LM, Eng C, Healey CS et al. Specific mutations of
the RET protooncogene are related to disease phenotype in
MEN 2A and FMTC. Nat Genet. 1994;6:7074.
96. FrankRaue K, Hoppner W, Frilling A et al. Mutations of the ret
protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin
Endocrinol Metab. 1996;81(5):17801783.
97. Machens A, NiccoliSire P, Hoegel J et al. Early malignant
progression of hereditary medullary thyroid cancer. N Engl J
Med. 2003;349(16):15171525.
98. Romei C, Cosci B, Renzini G et al. RET genetic screening of
sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC
(FMTC). Clin Endocrinol. 2011;74(2):241247.
99. Miyauchi A, Futami H, Hai N et al. Two germline missense
mutations at codons 804 and 806 of the RET protooncogene
in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res.
1999;90(1):15.
100. Menko FH, van der Luijt RB, DeValketal IAJ. Atypical MEN
type 2B associated with two germline RET mutations on the
same allele not involving codon 918. J Clin Endocrinol Metab.
2002;87(1):393397.
101. NiccoliSire P, Murat A, Rohmer V et al. Familial medullary
thyroid carcinoma with noncysteine RET mutations: phenotypegenotype relationship in a large series of patients. J Clin
Endocrinol Metab. 2001;86(8):37463753.
102. Erdogan MF, Gürsoy A, Özgen G et al. Ret protooncogene
mutations in apparently sporadic Turkish medullary thyroid
carcinoma patients: Turkmen study. J Endocrinol Invest.
2005;28(9):806809.
103. Eng C, Mulligan LM, Smith DP et al. Low frequency of
germline mutations in the RET protooncogene in patients with
apparently sporadic medullary thyroid carcinoma. Clin
Endocrinol. 1995;43(1):123127.
104. Orgiana G, Pinna G, Camedda A et al. A new germline RET
mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thy
roiditis and primary ovarian failure. J Clin

Up-to-date view on diagnostics and treatment of medullary thyroid cancer

During last 4 years leading endocrine societies of the world published clinical recommendations on diagnostics and treatment of medullary thyroid cancer. The article covers most aspects of following patients with this pathology.

Keywords:
medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, calcitonin, CEA, RET-proto-oncogene.